Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allakos Inc.ALLK · Entity 79644 | member - potential 10% group | March 03, 2021 | March 06, 2021 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | May 28, 2026 | June 01, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allakos Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,154 |
Reported balance
After 2021-03-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-03-03 · Sale · Disposed 400 · Balance 32,154 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.24 - $111.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F4: Shares held prior to the reported transaction consisted of 32,554 shares received in a pro rata distribution from APNG I subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16. |
| Common StockSEC Table I · non-derivative | Direct | 30,254 |
Reported balance
After 2021-03-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-03-03 · Sale · Disposed 1,900 · Balance 30,254 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.265 - $112.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 29,954 |
Reported balance
After 2021-03-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2021-03-03 · Sale · Disposed 300 · Balance 29,954 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 - $112.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 29,554 |
Reported balance
After 2021-03-03 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2021-03-03 · Sale · Disposed 400 · Balance 29,554 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.38 - $114.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 27,676 |
Reported balance
After 2021-03-03 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2021-03-03 · Sale · Disposed 1,878 · Balance 27,676 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.005 - $115.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 26,576 |
Reported balance
After 2021-03-04 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2021-03-04 · Sale · Disposed 1,100 · Balance 26,576 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.09 - $108.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 23,780 |
Reported balance
After 2021-03-04 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2021-03-04 · Sale · Disposed 2,796 · Balance 23,780 F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 - $110.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 21,970 |
Reported balance
After 2021-03-04 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2021-03-04 · Sale · Disposed 1,810 · Balance 21,970 F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 - $111.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 18,690 |
Reported balance
After 2021-03-04 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2021-03-04 · Sale · Disposed 3,280 · Balance 18,690 F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.43 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 12,776 |
Reported balance
After 2021-03-04 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2021-03-04 · Sale · Disposed 5,914 · Balance 12,776 F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.54 - $113.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 12,676 |
Reported balance
After 2021-03-04 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2021-03-04 · Sale · Disposed 100 · Balance 12,676 |
| Common StockSEC Table I · non-derivative | Direct | 10,076 |
Reported balance
After 2021-03-05 transaction · row 13
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 13 · 2021-03-05 · Sale · Disposed 2,600 · Balance 10,076 F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.25 - $116.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 6,205 |
Reported balance
After 2021-03-05 transaction · row 14
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 14 · 2021-03-05 · Sale · Disposed 3,871 · Balance 6,205 F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.25 - $117.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 4,505 |
Reported balance
After 2021-03-05 transaction · row 15
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 15 · 2021-03-05 · Sale · Disposed 1,700 · Balance 4,505 F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.27 - $118.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 3,205 |
Reported balance
After 2021-03-05 transaction · row 16
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 16 · 2021-03-05 · Sale · Disposed 1,300 · Balance 3,205 F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 - $119.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 1,605 |
Reported balance
After 2021-03-05 transaction · row 17
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 17 · 2021-03-05 · Sale · Disposed 1,600 · Balance 1,605 F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.29 - $120.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 605 |
Reported balance
After 2021-03-05 transaction · row 18
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 18 · 2021-03-05 · Sale · Disposed 1,000 · Balance 605 F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.53 - $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-05 transaction · row 19
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 19 · 2021-03-05 · Sale · Disposed 605 · Balance 0 F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.60 - $122.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,071,147 |
Reported balance
Holding disclosure · report date 2021-03-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,071,147 F1: Reflects a distribution in kind effected by Alta Partners NextGen Fund I L.P. ("APNG I") subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16. F2: These shares are directly held by APNG I. Alta Partners NextGen Fund I Management, LLC ("APNG I Management") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a distribution in kind effected by Alta Partners NextGen Fund I L.P. ("APNG I") subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16.
F2: These shares are directly held by APNG I. Alta Partners NextGen Fund I Management, LLC ("APNG I Management") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.24 - $111.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4: Shares held prior to the reported transaction consisted of 32,554 shares received in a pro rata distribution from APNG I subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.265 - $112.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 - $112.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.38 - $114.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.005 - $115.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.09 - $108.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 - $110.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 - $111.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.43 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.54 - $113.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.25 - $116.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.25 - $117.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.27 - $118.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 - $119.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.29 - $120.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.53 - $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.60 - $122.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Tyra Biosciences, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.68 · Expires 2036-05-27 | Direct | 13,160 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 13,160 · Balance 13,160 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Vir Biotechnology, Inc.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,656 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Other · Disposed 8,000 · Balance 40,656 F1: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 517,917 |
Reported balance
After 2026-08-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-11 · Other · Acquired 8,000 · Balance 517,917 F1: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. F2: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards.
F2: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 18:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056108 · wk-form4_1786559443.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 517,917 F1 · kind: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. F2 · ownership.nature: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056108 · wk-form4_1786559443.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,656 F1 · kind: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 13,160 | $0.00 Strike: $32.68 | $0.00 |
DisclosureSEC source: 0001193125-26-251534 · ownership.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,160 Underlying: Common Stock · 13,160 shares Expires 2036-05-27 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001628280-26-038964 · wk-form4_1780010697.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-05-26 F4 · shares: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027. Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-038964 · wk-form4_1780010697.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,656 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 27, 2027. Read SEC document |
| December 19, 2025 Filed Dec 20, 2025 02:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001193125-25-327254 · ownership.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,823,425 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025. F2 · ownership.nature: These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 22:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 246,871 | $20.25 | $5,000,026.49 |
DisclosureSEC source: 0001193125-25-297551 · ownership.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,833,425 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.25 to $21.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 22:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 14,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030306 · wk-form4_1749508754.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 509,917 F1 · kind: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. F2 · ownership.nature: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 22:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 14,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030306 · wk-form4_1749508754.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,656 F1 · kind: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 23:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0001628280-25-028894 · wk-form4_1748906520.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-29 F4 · shares: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 23:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028894 · wk-form4_1748906520.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,683 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 30, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:05 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 22,200 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0000950170-25-080230 · ownership.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,200 Underlying: Common Stock · 22,200 shares Expires 2035-05-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001628280-24-026207 · wk-form4_1717430899.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-05-29 Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-026207 · wk-form4_1717430899.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,683 Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 18,600 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0000950170-24-067361 · ownership.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2034-05-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 18:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034785 · wk-form4_1697825747.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 495,890 F2 · shares: Shares transferred for no consideration to APNG 1 upon vesting of an RSU award held by the Reporting Person for the benefit of APNG 1. F3 · ownership.nature: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 18:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034785 · wk-form4_1697825747.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,683 F1 · kind: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. F1 · shares: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0001209191-23-033775 · doc4.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 18:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 12,054 | $0.00 Strike: $25.74 | $0.00 |
DisclosureSEC source: 0001209191-23-031845 · doc4.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,054 Underlying: Common Stock · 12,054 shares Expires 2033-05-21 Read SEC document |
| May 22, 2023 Filed May 24, 2023 18:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 6,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031845 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,088 Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001209191-22-036981 · doc4.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2032-06-12 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:17 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 3,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036296 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 489,485 F2 · shares: Shares transferred for no consideration to APNG 1 upon vesting of an RSU award held by the Reporting Person for the benefit of APNG 1. F3 · ownership.nature: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:17 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 3,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036296 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,061 F1 · kind: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. F1 · shares: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 12,810 | $0.00 Strike: $24.14 | $0.00 |
DisclosureSEC source: 0001209191-22-031950 · doc4.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,810 Underlying: Common Stock · 12,810 shares Expires 2032-05-22 Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031950 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,435 Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 255,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036431 · doc4.xml · derivative · entry 4 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 662,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 1,212,122 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036431 · doc4.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,148,365 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | PurchaseCommon Stock | 156,250 | $16.00 | $2,500,000.00 |
DisclosureSEC source: 0000899243-21-036431 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,080,296 F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 3,811,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036431 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,924,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,348 | $37.58 | $88,243.01 |
DisclosureSEC source: 0001209191-21-049147 · doc4.xml · nonDerivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,030 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.22 to $37.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,322 | $36.63 | $341,479.78 |
DisclosureSEC source: 0001209191-21-049147 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,378 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $37.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 00:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,670 | $35.56 | $415,012.04 |
DisclosureSEC source: 0001209191-21-047285 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,029 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.18 to $36.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 890 | $46.22 | $41,133.04 |
DisclosureSEC source: 0001209191-21-045554 · doc4.xml · nonDerivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,699 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.91 to $46.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,986 | $45.23 | $270,731.82 |
DisclosureSEC source: 0001209191-21-045554 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,589 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,794 | $44.31 | $212,405.36 |
DisclosureSEC source: 0001209191-21-045554 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,575 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.81 to $44.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 01, 2021 Filed Aug 3, 2021 00:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 1,671 | $43.53 | $72,738.63 |
DisclosureSEC source: 0001209191-21-049147 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 F1 · kind: On July 1, 2021, the reporting person became entitled to receive 1,671 shares of the Issuer's common stock pursuant to an "earn-out" right in a letter agreement (the "Letter Agreement") entered into in connection with the Issuer's acquisition of all equity interests of TomegaVax, Inc. ("TomegaVax") on September 12, 2016 (the "TomegaVax Merger"). The Letter Agreement provides for certain payments to TomegaVax's former stockholders, for no additional consideration, prior to September 2024, in each case so long as the Issuer is continuing to pursue the development of the TomegaVax technology. F2 · kind: Under the terms of the Letter Agreement, the Issuer will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Issuer's publicly traded common stock, or implied price per share of the Issuer's Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Issuer's clinical development at the time of the relevant event triggering the payment. The share price of the Issuer's publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Issuer's common stock for each trading day during a consecutive 90-day period. F3 · kind: The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Issuer or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Issuer or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the Letter Agreement can be made in cash or shares of the Issuer's common stock, at the discretion of the Issuer's board of directors. On February 24, 2021, the Issuer achieved one of the milestones related to the specified per-share price of its common stock, which resulted in a $10.0 million payable to TomegaVax's former stockholders within 90 business days of achieving such milestone. F4 · kind: The number of shares issuable pursuant to the earn-out right was determined on July 1, 2021 (90 business days after the achievement of such milestone) based on the closing price of the Issuer's common stock on such date, as provided in the Letter Agreement. On July 9, 2021, the Issuer completed the milestone payment to the former TomegaVax stockholders, including the reporting person, through a combination of cash payment and shares of common stock as determined by the Issuer's board of directors. The reporting person's right to receive additional shares became fixed and irrevocable on September 12, 2016, the effective date of the TomegaVax Merger. F5 · kind: The remaining $20.0 million in milestone payments will be triggered if (i) the per-share price of the Issuer's publicly traded common stock is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Issuer's clinical development at the time of the relevant event triggering the payment or (ii) the per-share price of the Issuer's publicly traded common stock is at least $90 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization). The foregoing description of the terms of the Letter Agreement is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which was filed as Exhibit 10.31 to the Issuer's Annual Report on Form 10-K for the year-ended December 31, 2020 filed with the Securities and Exchange Commission on February 25, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,670 | $43.95 | $512,840.48 |
DisclosureSEC source: 0001209191-21-042116 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $44.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 03, 2021 Filed Jun 8, 2021 00:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,670 | $44.56 | $520,032.71 |
DisclosureSEC source: 0001209191-21-038772 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 6,748 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001209191-21-035709 · doc4.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,748 Underlying: Common Stock · 6,748 shares Expires 2031-05-20 Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 3,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035709 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,709 Read SEC document |
| May 20, 2021 Filed May 25, 2021 01:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,095 | $44.77 | $407,153.14 |
DisclosureSEC source: 0001209191-21-035596 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,335 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.22 to $45.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 20, 2021 Filed May 25, 2021 01:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,575 | $43.57 | $112,198.16 |
DisclosureSEC source: 0001209191-21-035596 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,430 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.16 to $44.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 30,354 shares received in a pro-rata distribution from Alta Partners NextGen Fund I, L.P. (APNG 1) which was effected on April 5, 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 605 | $121.65 | $73,598.25 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 19 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.60 - $122.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,000 | $120.83 | $120,830.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 18 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605 F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.53 - $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,600 | $119.70 | $191,520.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 17 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605 F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.29 - $120.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,300 | $118.85 | $154,505.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 16 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,205 F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 - $119.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,700 | $117.62 | $199,954.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 15 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,505 F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.27 - $118.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 3,871 | $116.63 | $451,474.73 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 14 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,205 F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.25 - $117.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 2,600 | $115.83 | $301,158.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 13 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,076 F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.25 - $116.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 100 | $114.14 | $11,414.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 12 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,676 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.